Abstract:BackgroundEquine melanoma has a high incidence in grey horses. Xenogenic DNA vaccination may represent a promising therapeutic approach against equine melanoma as it successfully induced an immunological response in other species suffering from melanoma and in healthy horses. In a clinical study, twenty-seven, grey, melanoma-bearing, horses were assigned to three groups (n = 9) and vaccinated on days 1, 22, and 78 with DNA vectors encoding for equine (eq) IL-12 and IL-18 alone or in combination with either human glycoprotein (hgp) 100 or human tyrosinase (htyr). Horses were vaccinated intramuscularly, and one selected melanoma was locally treated by intradermal peritumoral injection. Prior to each injection and on day 120, the sizes of up to nine melanoma lesions per horse were measured by caliper and ultrasound. Specific serum antibodies against hgp100 and htyr were measured using cell based flow-cytometric assays. An Analysis of Variance (ANOVA) for repeated measurements was performed to identify statistically significant influences on the relative tumor volume. For post-hoc testing a Tukey-Kramer Multiple-Comparison Test was performed to compare the relative volumes on the different examination days. An ANOVA for repeated measurements was performed to analyse changes in body temperature over time. A one-way ANOVA was used to evaluate differences in body temperature between the groups. A p–value < 0.05 was considered significant for all statistical tests applied.ResultsIn all groups, the relative tumor volume decreased significantly to 79.1 ± 26.91% by day 120 (p < 0.0001, Tukey-Kramer Multiple-Comparison Test). Affiliation to treatment group, local treatment and examination modality had no significant influence on the results (ANOVA for repeated measurements). Neither a cellular nor a humoral immune response directed against htyr or hgp100 was detected. Horses had an increased body temperature on the day after vaccination.ConclusionsThis is the first clinical report on a systemic effect against equine melanoma following treatment with DNA vectors encoding eqIL12 and eqIL18 and formulated with a transfection reagent. Addition of DNA vectors encoding hgp100 respectively htyr did not potentiate this effect.

Treatment Options for Melanoma of Gray Horses

Equine Melanocytic Tumors: A Narrative Review

Equine Melanoma Updates

A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse

Coat color genotypes and risk and severity of melanoma in gray quarter horses

Complex inheritance of melanoma and pigmentation of coat and skin in Grey horses

Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses

Hair Graying Regulators Beyond Hair Follicle

Copy number expansion of the STX17 duplication in melanoma tissue from Grey horses

Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma

Identification of a melanocyte-specific, microphthalmia-associated transcription factor-dependent regulatory element in the intronic duplication causing hair greying and melanoma in horses

Interventions for Treatment of Cutaneous Melanoma in Horses: a Structured Literature Review

Deregulation of Metalloproteinase Expression in Gray Horse Melanoma Ex Vivo and In Vitro

Environmental risk factors for UV-induced cutaneous neoplasia in horses: A GIS approach

Non-Surgical Treatment Methodologies and Prevention for Malignant Melanoma

An intronic copy number variation in Syntaxin 17 determines speed of greying and melanoma incidence in Grey horses

Reversal of premature hair graying treated with a topical formulation containing α-melanocyte-stimulating hormone agonist (Greyverse Solution 2%)

Melanocyte stem cells as potential therapeutics in skin disorders

Melanocortin-1 receptor mutations and pigmentation: Insights from large animals

Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines

Clinical Characteristics and Treatment Outcomes of Pigmented Tumors in Central Nervous System: Focusing on Melanocytic Tumors